Cell and Gene Therapy Market Global Report 2026

The cell and gene therapy market size has grown exponentially in recent years. It will grow from $15.99 billion in 2025 to $19.68 billion in 2026 at a compound annual growth rate (CAGR) of 23.1%. The growth in the historic period can be attributed to the limited availability of cell and gene therapy treatments, continued dependence on conventional therapeutic approaches, high costs associated with early-generation therapies, increasing prevalence of oncology and neurological conditions, and insufficient availability of specialized treatment centers.

The cell and gene therapy market size is expected to see exponential growth in the next few years. It will grow to $43.95 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to advancements in CAR-T and genome editing therapies, expansion of clinical trials and research initiatives, increasing uptake of personalized medicine, growing government funding and support for rare disease treatments, and greater integration of digital platforms for therapy monitoring and patient management. Major trends in the forecast period include increasing adoption of CAR-T and stem cell therapies, rising investments in gene therapy applications for oncology and rare diseases, expansion of personalized and targeted cell-based treatments, increasing availability of advanced therapies through hospitals and ambulatory surgical centers, and growing integration of genome editing and viral vector technologies into clinical practice.

The increasing number of ongoing clinical trials is expected to drive the growth of the cell and gene therapy market in the coming years. Clinical trials are structured research studies involving human participants that are conducted to assess the safety and efficacy of new medical treatments, interventions, or diagnostic methods. These trials are essential to the development and progress of cell and gene therapies because they provide controlled settings for evaluating emerging treatments and generating evidence regarding their safety and effectiveness. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials initiated in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the increasing number of ongoing clinical trials is driving the growth of the cell and gene therapy market.

Leading companies operating in the cell and gene therapy market are increasing their focus on introducing agnostic systems to strengthen their competitive position in the market. Agnostic systems refer to systems that can integrate with a range of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For example, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system designed to improve connectivity across the cell and gene therapy (CGT) treatment journey and enhance the patient and provider experience. The hub is powered by the company's customer relationship management system and is designed to accelerate the benefits investigation process, provide a real-time view of therapy development and transportation status, and support the coordination of patient assistance.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company engaged in the development and commercialization of medicines to improve human health and well-being globally, acquired Orchard Therapeutics for an undisclosed amount. Through this acquisition, Kyowa Kirin Co., Ltd. aims to strengthen its capabilities in developing innovative gene therapies for rare diseases, expand its therapeutic portfolio, and address areas of significant unmet medical need. Orchard Therapeutics plc is a UK-based biotechnology company specializing in the development of innovative cell and gene therapies.

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca.

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

This product will be delivered within 1-3 business days.